Lutetium-177 Vipivotide Tetraxetan
Drug timelines are a Plus or Pro feature.
3 regulatory and trial events tracked for Lutetium-177 Vipivotide Tetraxetan, covering 2025-12-31 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) [Phase 2]